2006 - Memantine NOT effective for Depression
1: Am J Psychiatry. 2006 Jan;163(1):153-5. Links
A double-blind, placebo-controlled study of memantine in the treatment of major depression.
Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS.
10 Center Dr., Mark O. Hatfield CRC, 7 SE, Rm. 7-3445, Bethesda, MD 20892. zaratec@mail.nih.gov.
OBJECTIVE:
This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.
METHOD:
In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).
RESULTS:
The linear mixed models for total MADRS scores showed no treatment effect.
CONCLUSIONS:
In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.
PMID: 16390905 [PubMed - in process]
ncbi.nlm.nih.gov |
